Global Peanut Allergy Treatment Market by Treatment Type (Immunotherapy, Medications, Biologic Therapies), End-Use Industry (Hospitals, Allergy Clinics, Research Institutions), Formulation (Oral Treatments, Injectable Treatments, Sublingual Treatments): Insights & Forecast (2024 – 2030)

As per Intent Market Research, the Peanut Allergy Treatment Market was valued at USD 2.5 Billion in 2024-e and will surpass USD 8.7 Billion by 2030; growing at a CAGR of 23.1% during 2025 - 2030.

The peanut allergy treatment market is gaining significant traction as the global prevalence of food allergies, especially peanut allergies, continues to rise. Peanut allergies can cause severe and life-threatening reactions, creating an urgent need for effective treatments. Over the years, treatment options have evolved from managing symptoms with medications to more advanced therapeutic strategies such as immunotherapy and biologic therapies. As awareness about peanut allergies increases, particularly among children, and as research progresses in the development of more effective and personalized treatments, the market is poised for significant growth. The introduction of novel therapies, including oral immunotherapy and biologics, is expected to shape the future of peanut allergy treatment, offering new hope to those affected by this potentially dangerous allergy.

In addition to traditional methods, emerging treatment options are being developed to provide long-term relief or even desensitization to peanut allergens. These therapies aim not only to alleviate symptoms but to address the root cause of the allergic response. With growing research efforts and the increasing availability of treatment options, the market is expected to continue its upward trajectory, creating a larger patient base and attracting new industry players.

Immunotherapy Is Fastest Growing Treatment Type Owing to Promising Desensitization Benefits

Immunotherapy is the fastest-growing treatment type in the peanut allergy treatment market due to its promising potential for desensitizing patients to peanut allergens. Unlike traditional medications, which focus on symptom management, immunotherapy targets the underlying allergic reaction, gradually training the immune system to tolerate peanuts. Oral immunotherapy (OIT) has been one of the most widely studied and implemented forms of immunotherapy for peanut allergies. This treatment involves administering increasing doses of peanut protein over time, which helps patients build tolerance to the allergen and reduce the severity of allergic reactions.

Immunotherapy is transforming the way peanut allergies are managed, with ongoing clinical trials indicating significant success in enhancing tolerance. This treatment offers long-term benefits and a more permanent solution compared to medications that only address immediate symptoms. As research continues to validate its effectiveness and as more patients experience successful outcomes, immunotherapy is expected to gain widespread adoption, making it the fastest-growing segment in the market.

Oral Treatments Are Largest Formulation Type Due to Ease of Administration and High Patient Preference

Oral treatments are the largest formulation type in the peanut allergy treatment market, owing to their ease of administration and the high preference among patients, particularly children. Oral immunotherapy (OIT), in which patients consume small, controlled amounts of peanut protein, is the most common form of oral treatment. This approach has proven to be both effective and relatively convenient, allowing patients to receive treatment at home under controlled conditions. Oral treatments have been shown to significantly reduce allergic reactions and provide patients with a degree of protection from accidental peanut exposure, which is a critical factor for those with severe allergies.

The widespread adoption of oral treatments can be attributed to the simplicity and non-invasiveness of this method compared to injectables. As a result, oral treatments are considered the go-to choice for peanut allergy therapy, particularly among families who prefer less invasive options. As new formulations and delivery methods are introduced to enhance the effectiveness and safety of oral treatments, the segment is expected to maintain its dominance in the market.

Hospitals Are Largest End-Use Industry Due to High Demand for Specialized Allergy Care

Hospitals represent the largest end-use industry in the peanut allergy treatment market, primarily due to the high demand for specialized care for patients with severe allergic reactions. Hospitals provide comprehensive care for peanut allergy patients, including diagnostic testing, emergency treatments, and long-term management strategies. In cases of severe allergic reactions, hospitals are equipped to provide immediate care, including the administration of epinephrine and other life-saving interventions. Additionally, many hospitals are participating in clinical trials for new treatments and therapies, making them key players in advancing peanut allergy research.

As peanut allergy awareness grows, hospitals are becoming increasingly involved in the management and treatment of the condition. They offer specialized allergy clinics, immunotherapy programs, and other services to support patients throughout their treatment journey. The prevalence of peanut allergies, particularly among children, further contributes to the dominance of hospitals in this market, as these medical centers are often the first point of care for both diagnosis and treatment.

North America Is Largest Region in the Peanut Allergy Treatment Market Owing to High Prevalence

North America dominates the Peanut Allergy Treatment Market, driven by the high prevalence of peanut allergies and the region's advanced healthcare systems. The United States, in particular, has seen a significant rise in peanut allergies, especially among children, leading to an increased focus on effective treatments and therapies. As the demand for innovative peanut allergy treatments grows, healthcare providers in North America are actively adopting novel immunotherapies, epinephrine injectors, and other advanced treatment options.

The region benefits from well-established healthcare infrastructure, extensive research and development activities, and strong regulatory frameworks that support the development and approval of new treatments. In addition, increased awareness and public health initiatives related to peanut allergies further contribute to the rapid adoption of treatments. As a result, North America remains the largest market for peanut allergy treatments, with substantial investments being made to address this growing health concern.

Competitive Landscape and Key Players

The peanut allergy treatment market is competitive, with a mix of established pharmaceutical companies and innovative biotech firms vying to develop and commercialize new therapies. Major pharmaceutical players like DBV Technologies, Aimmune Therapeutics, and Regeneron Pharmaceuticals are leading the development of immunotherapy-based treatments. Aimmune’s Palforzia, the first FDA-approved oral immunotherapy for peanut allergies, represents a significant milestone in the field and is helping to shape the future of peanut allergy treatment.

In addition to these leaders, several other biotech companies are focusing on biologic therapies and alternative treatment modalities. Companies are investing heavily in research and development to create more effective, safer treatments with fewer side effects. The competitive landscape is also marked by ongoing collaborations between pharmaceutical companies, research institutions, and healthcare providers to advance peanut allergy therapies. As the market continues to expand, new entrants with innovative solutions will contribute to the growth and evolution of the peanut allergy treatment landscape.

List of Leading Companies:

• DBV Technologies
• Aimmune Therapeutics
• Regeneron Pharmaceuticals
• Sanofi
• Merck & Co., Inc.
• Mylan (now part of Viatris)
• GlaxoSmithKline
• Allergy Therapeutics
• Argenx
• Novartis
• Eli Lilly and Co.
• Bayer
• Teva Pharmaceuticals
• Sunovion Pharmaceuticals
• Immunomedics

Recent Developments:

• DBV Technologies announced positive Phase 3 trial results for its peanut allergy patch, aiming for FDA approval for peanut allergy treatment in children.
• Aimmune Therapeutics received FDA approval for Palforzia, an oral immunotherapy treatment for peanut allergies, to be used in patients aged 4 to 17.
• Regeneron Pharmaceuticals launched a new biologic therapy for peanut allergies, showing promise in reducing allergic responses in clinical trials.
• Sanofi entered into a partnership with an allergy therapeutics company to develop new peanut allergy treatment options using innovative biologic therapies.
• Merck & Co., Inc. announced that it will expand its research on peanut allergy immunotherapy, focusing on oral treatments to improve patient outcomes.

Report Scope: